Cargando…

Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification

Hepatic organoids are a recent innovation in in vitro modeling. Initial studies suggest that organoids better recapitulate the liver phenotype in vitro compared to pre-existing proliferative cell models. However, their potential for drug metabolism and detoxification remains poorly characterized, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Howell, Lawrence, Jenkins, Rosalind E., Lynch, Stephen, Duckworth, Carrie, Kevin Park, B., Goldring, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241807/
https://www.ncbi.nlm.nih.gov/pubmed/34050779
http://dx.doi.org/10.1007/s00204-021-03075-3
_version_ 1783715492509253632
author Howell, Lawrence
Jenkins, Rosalind E.
Lynch, Stephen
Duckworth, Carrie
Kevin Park, B.
Goldring, Christopher
author_facet Howell, Lawrence
Jenkins, Rosalind E.
Lynch, Stephen
Duckworth, Carrie
Kevin Park, B.
Goldring, Christopher
author_sort Howell, Lawrence
collection PubMed
description Hepatic organoids are a recent innovation in in vitro modeling. Initial studies suggest that organoids better recapitulate the liver phenotype in vitro compared to pre-existing proliferative cell models. However, their potential for drug metabolism and detoxification remains poorly characterized, and their global proteome has yet to be compared to their tissue of origin. This analysis is urgently needed to determine what gain-of-function this new model may represent for modeling the physiological and toxicological response of the liver to xenobiotics. Global proteomic profiling of undifferentiated and differentiated hepatic murine organoids and donor-matched livers was, therefore, performed to assess both their similarity to liver tissue, and the expression of drug-metabolizing enzymes and transporters. This analysis quantified 4405 proteins across all sample types. Data are available via ProteomeXchange (PXD017986). Differentiation of organoids significantly increased the expression of multiple cytochrome P450, phase II enzymes, liver biomarkers and hepatic transporters. While the final phenotype of differentiated organoids is distinct from liver tissue, the organoids contain multiple drug metabolizing and transporter proteins necessary for liver function and drug metabolism, such as cytochrome P450 3A, glutathione-S-transferase alpha and multidrug resistance protein 1A. Indeed, the differentiated organoids were shown to exhibit increased sensitivity to midazolam (10–1000 µM) and irinotecan (1–100 µM), when compared to the undifferentiated organoids. The predicted reduced activity of HNF4A and a resulting dysregulation of RNA polymerase II may explain the partial differentiation of the organoids. Although further experimentation, optimization and characterization is needed relative to pre-existing models to fully contextualize their use as an in vitro model of drug-induced liver injury, hepatic organoids represent an attractive novel model of the response of the liver to xenobiotics. The current study also highlights the utility of global proteomic analyses for rapid and accurate evaluation of organoid-based test systems. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00204-021-03075-3.
format Online
Article
Text
id pubmed-8241807
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-82418072021-07-14 Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification Howell, Lawrence Jenkins, Rosalind E. Lynch, Stephen Duckworth, Carrie Kevin Park, B. Goldring, Christopher Arch Toxicol Toxicogenomics and Omics Technologies Hepatic organoids are a recent innovation in in vitro modeling. Initial studies suggest that organoids better recapitulate the liver phenotype in vitro compared to pre-existing proliferative cell models. However, their potential for drug metabolism and detoxification remains poorly characterized, and their global proteome has yet to be compared to their tissue of origin. This analysis is urgently needed to determine what gain-of-function this new model may represent for modeling the physiological and toxicological response of the liver to xenobiotics. Global proteomic profiling of undifferentiated and differentiated hepatic murine organoids and donor-matched livers was, therefore, performed to assess both their similarity to liver tissue, and the expression of drug-metabolizing enzymes and transporters. This analysis quantified 4405 proteins across all sample types. Data are available via ProteomeXchange (PXD017986). Differentiation of organoids significantly increased the expression of multiple cytochrome P450, phase II enzymes, liver biomarkers and hepatic transporters. While the final phenotype of differentiated organoids is distinct from liver tissue, the organoids contain multiple drug metabolizing and transporter proteins necessary for liver function and drug metabolism, such as cytochrome P450 3A, glutathione-S-transferase alpha and multidrug resistance protein 1A. Indeed, the differentiated organoids were shown to exhibit increased sensitivity to midazolam (10–1000 µM) and irinotecan (1–100 µM), when compared to the undifferentiated organoids. The predicted reduced activity of HNF4A and a resulting dysregulation of RNA polymerase II may explain the partial differentiation of the organoids. Although further experimentation, optimization and characterization is needed relative to pre-existing models to fully contextualize their use as an in vitro model of drug-induced liver injury, hepatic organoids represent an attractive novel model of the response of the liver to xenobiotics. The current study also highlights the utility of global proteomic analyses for rapid and accurate evaluation of organoid-based test systems. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00204-021-03075-3. Springer Berlin Heidelberg 2021-05-29 2021 /pmc/articles/PMC8241807/ /pubmed/34050779 http://dx.doi.org/10.1007/s00204-021-03075-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Toxicogenomics and Omics Technologies
Howell, Lawrence
Jenkins, Rosalind E.
Lynch, Stephen
Duckworth, Carrie
Kevin Park, B.
Goldring, Christopher
Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification
title Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification
title_full Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification
title_fullStr Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification
title_full_unstemmed Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification
title_short Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification
title_sort proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification
topic Toxicogenomics and Omics Technologies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241807/
https://www.ncbi.nlm.nih.gov/pubmed/34050779
http://dx.doi.org/10.1007/s00204-021-03075-3
work_keys_str_mv AT howelllawrence proteomicprofilingofmurinebiliaryderivedhepaticorganoidsandtheircapacityfordrugdispositionbioactivationanddetoxification
AT jenkinsrosalinde proteomicprofilingofmurinebiliaryderivedhepaticorganoidsandtheircapacityfordrugdispositionbioactivationanddetoxification
AT lynchstephen proteomicprofilingofmurinebiliaryderivedhepaticorganoidsandtheircapacityfordrugdispositionbioactivationanddetoxification
AT duckworthcarrie proteomicprofilingofmurinebiliaryderivedhepaticorganoidsandtheircapacityfordrugdispositionbioactivationanddetoxification
AT kevinparkb proteomicprofilingofmurinebiliaryderivedhepaticorganoidsandtheircapacityfordrugdispositionbioactivationanddetoxification
AT goldringchristopher proteomicprofilingofmurinebiliaryderivedhepaticorganoidsandtheircapacityfordrugdispositionbioactivationanddetoxification